Welcome to our dedicated page for Cbdmd SEC filings (Ticker: YCBD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
cbdMD, Inc. filings document a North Carolina cannabinoid-products company with disclosures covering securities registration, capital structure, governance and material agreements.
The record includes Securities Act registration statements, proxy disclosures on executive compensation and shareholder matters, and 8-K reports on director equity compensation, board fees, operating and financial results, and the completed Bluebird Botanicals asset purchase, including acquired brand, online marketplace, trademarks, inventory and share-based consideration.
cbdMD, Inc. has extended and restructured the lease for its combined warehouse and executive offices at 2101 Westinghouse Boulevard in Charlotte, North Carolina.
The Third Amendment to Lease extends the term for 62 months beginning on October 1, 2026, creating a new expiration date of November 30, 2031 for 40,000 square feet of space. The amendment reduces monthly base rent to $38,000 for the initial year of the renewal term, with annual base rent of $9.75 per square foot from March 1, 2025 through February 28, 2026, increasing up to $13.87 per square foot for the final two months of the term. Monthly base rent is fully abated from October 1, 2026 through November 30, 2026.
Management states that reducing the leased footprint to 40,000 square feet is sufficient for current and expected operations and that remaining in the current facility aligns with the company’s long-term needs. The company estimates an annual reduction in gross rent expense of approximately $450,000 and a net rent expense reduction of about $100,000 to $120,000 per year after accounting for ongoing sublet income.
cbdMD, Inc. reported higher quarterly sales but continued losses and warned about its ability to continue as a going concern. For the quarter ended March 31, 2026, net sales rose to $5.6 million, up from $4.7 million a year earlier, driven by growth in both e‑commerce and wholesale channels and initial contributions from the Bluebird acquisition.
Gross margin declined to 57.7%, and the company posted a net loss attributable to common shareholders of $876,783, though this was an improvement from the prior‑year loss due to lower preferred dividends. For the six‑month period, net sales were $10.7 million with a net loss attributable to common shareholders of $1.2 million. Cash was $2.6 million and working capital $5.4 million as of March 31, 2026, but management highlighted substantial doubt about continuing as a going concern, ongoing preferred dividend obligations, and potentially material adverse impacts from federal hemp legislation.
Porter Jeffrey H reported acquisition or exercise transactions in this Form 4 filing.
cbdMD, Inc. director Jeffrey H. Porter reported receiving a grant of 1,572 restricted stock units of common stock on April 14, 2026 as compensation for his Board service. After this award, he directly holds 3,144 common shares and also controls sizable indirect holdings through several related entities.
Roe Kevin Charles reported acquisition or exercise transactions in this Form 4 filing.
cbdMD, Inc. director Kevin Charles Roe received a grant of 1,572 restricted stock units, each representing a right to one share of common stock, as compensation for Board service under the company’s 2021 or 2025 Equity Compensation Plan.
The award was approved by the Compensation, Corporate Governance and Nominating Committee and carries a stated price of $0.00 per unit, reflecting its nature as equity compensation rather than a market purchase. The restricted stock units vest quarterly on June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027. Following this grant, Roe directly holds 26,707 shares or share-equivalent units of cbdMD common stock.
Swift Sibyl Nichole reported acquisition or exercise transactions in this Form 4 filing.
cbdMD, Inc. director Sibyl Nichole Swift received a grant of 1,572 shares of Common Stock on April 14, 2026 as an equity award, bringing her direct holdings to 4,145 shares. The award is in the form of restricted stock units, each representing a right to one share of common stock.
The restricted stock units were granted as compensation for her service on the Board of Directors under the company’s 2021 or 2025 Equity Compensation Plan. They vest in four quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026, and March 31, 2027, and were approved in advance by the Compensation, Corporate Governance and Nominating Committee.
Sellers Bakari T. reported acquisition or exercise transactions in this Form 4 filing.
cbdMD, Inc. director Bakari T. Sellers reported an equity compensation grant of 1,572 shares of common stock in the form of restricted stock units at no cash cost per share. Following this award, his directly held equity position increased to 4,324 shares.
The restricted stock units vest in four quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, aligning compensation with ongoing Board service under cbdMD’s 2021 or 2025 Equity Compensation Plan.
Stephen Scott G. reported acquisition or exercise transactions in this Form 4 filing.
cbdMD, Inc. director Stephen Scott G. received a grant of 1,572 restricted stock units as compensation for serving on the Board of Directors. Each unit represents one share of common stock and will vest in four quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026, and March 31, 2027. Following this award, he holds 4,412 shares of common stock directly.
Raines William F III reported acquisition or exercise transactions in this Form 4 filing.
cbdMD, Inc. director William F. Raines III received a grant of 1,572 restricted stock units, each representing one share of common stock, as compensation for his service on the board. The grant carried no cash purchase price.
The restricted stock units vest in four quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026, and March 31, 2027, under the company’s 2021 or 2025 Equity Compensation Plan. Following this award, Raines holds 13,676 shares of the company’s common stock directly.
cbdMD, Inc. updated its director compensation program. On April 14, 2026, the board granted each independent director and the non-management employee director 1,572 restricted stock units (RSUs) under the 2025 Equity Compensation Plan for the term beginning March 31, 2026. These RSUs vest in four equal quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, with value based on the common stock closing price on April 14, 2026. The board also set annual cash fees, including a $35,000 retainer per independent director and additional amounts for the board chair and key committee roles.
cbdMD, Inc. reported that shareholders approved its 2025 Equity Compensation Plan, creating a new stock-based incentive program for employees, directors and consultants. The plan initially reserves 891,316 shares of common stock for options, restricted stock and other equity awards.
The plan includes an evergreen formula that can increase the share pool each year by 2% of shares outstanding on September 30, up to 300,000 shares annually. With shareholder approval, a previously contingent 445,000-share restricted stock award to CEO and CFO T. Ronan Kennedy became effective. At the 2026 annual meeting, 10,495,561 shares were entitled to vote and a quorum of 54.6% was reached, with all seven proposals approved.